KRAS and colorectal carcinoma: Collectively, these data show that AHCY inhibition truncates the methionine cycle and thereby reduces proliferation and tumorigenesis of APC-deficient cells indicating its potential as an actionable target for APC-driven CRC, even in the context of mutant KRAS.